

By Senator Bean

4-00744A-19

2019706\_\_

1                                   A bill to be entitled  
2       An act relating to institutional pharmacies; amending  
3       s. 465.003, F.S.; revising the definition of the term  
4       "institutional formulary system"; amending s. 465.019,  
5       F.S.; authorizing the use of an institutional  
6       formulary system in a Class I institutional pharmacy;  
7       specifying requirements for the policies and  
8       procedures of an institutional formulary system in a  
9       Class I institutional pharmacy; providing an effective  
10      date.

11  
12 Be It Enacted by the Legislature of the State of Florida:

13  
14       Section 1. Subsection (7) of section 465.003, Florida  
15       Statutes, is amended to read:

16       465.003 Definitions.—As used in this chapter, the term:

17       (7) "Institutional formulary system" means a method whereby  
18       the medical staff evaluates, appraises, and selects those  
19       medicinal drugs or proprietary preparations that, which in the  
20       clinical judgment of the medical staff, ~~staff's clinical~~  
21       judgment are most useful in patient care, ~~and which~~ are  
22       available for dispensing by a practicing pharmacist for a Class  
23       I institutional pharmacy, or a practicing pharmacist in a Class  
24       II institutional pharmacy or a Class III institutional pharmacy,  
25       as those terms are defined in s. 465.019(2).

26       Section 2. Subsection (6) of section 465.019, Florida  
27       Statutes, is amended, subsection (7) is added to that section,  
28       and paragraph (a) of subsection (2) of that section is  
29       republished, to read:

4-00744A-19

2019706\_\_

30 465.019 Institutional pharmacies; permits.—

31 (2) The following classes of institutional pharmacies are  
32 established:

33 (a) "Class I institutional pharmacies" are those  
34 institutional pharmacies in which all medicinal drugs are  
35 administered from individual prescription containers to the  
36 individual patient and in which medicinal drugs are not  
37 dispensed on the premises, except that nursing homes licensed  
38 under part II of chapter 400 may purchase medical oxygen for  
39 administration to residents. No medicinal drugs may be dispensed  
40 in a Class I institutional pharmacy.

41 (6) In a Class I institutional pharmacy, a Class II  
42 institutional pharmacy, or a Class III institutional pharmacy,  
43 an institutional formulary system may be adopted with approval  
44 of the medical staff for the purpose of identifying those  
45 medicinal drugs, proprietary preparations, biologics,  
46 biosimilars, and biosimilar interchangeables that may be  
47 dispensed by a practicing pharmacist for a Class I institutional  
48 pharmacy, or dispensed by a practicing pharmacist in a Class II  
49 institutional pharmacy or a Class III institutional pharmacy,  
50 who is employed by the institutional pharmacy ~~the pharmacists~~  
51 ~~employed in such institution~~. A facility that has with a Class I  
52 institutional pharmacy permit, a Class II institutional pharmacy  
53 permit, or a Class III institutional pharmacy permit which is  
54 operating under the formulary system shall establish policies  
55 and procedures for the development of the system, in accordance  
56 with the joint standards of the American Hospital Association  
57 and American Society of Hospital Pharmacists, for the use  
58 ~~utilization~~ of an institutional ~~a hospital~~ formulary system,

4-00744A-19

2019706\_\_

59 which must ~~formulary shall~~ be approved by the medical staff.

60 (7) The policies and procedures for an institutional  
61 formulary system in a Class I institutional pharmacy must:

62 (a) Be approved by the medical staff.

63 (b) Openly provide detailed methods and criteria for the  
64 selection and objective evaluation of all available  
65 pharmaceuticals.

66 (c) Include policies for the development, maintenance,  
67 approval, dissemination, and notification to prescribers of the  
68 drug formulary and for continuous and comprehensive review of  
69 formulary drugs.

70 (d) Provide for regular monitoring of compliance with the  
71 policies and procedures and of clinical outcomes in  
72 circumstances in which a substitution of drugs has occurred.

73 (e) Provide a mechanism to inform the prescriber prior to  
74 any substitution of drugs by using a method of communication  
75 designated by the prescriber for such purpose. The method of  
76 communication designated by the prescriber must be noted in the  
77 patient's chart.

78 (f) Establish a process that allows any individual  
79 prescriber to opt out of the formulary system.

80 (g) Establish a process that allows any individual  
81 prescriber to opt out of the formulary system only with respect  
82 to a particular patient.

83 (h) Include policies stating that practitioners will not be  
84 penalized for prescribing nonformulary drug products that are  
85 medically necessary.

86 (i) Be consistent with applicable state and federal laws  
87 and with rules of the department and board.

4-00744A-19

2019706\_\_

88

Section 3. This act shall take effect July 1, 2019.